Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than or equal to 55 years;~* Subfoveal CNV secondary to AMD and with best corrected visual acuity of 3/60 - 6/9 with 6/60 or better in the other eye;~* Fluorescein angiogram of the study eye must show evidence of a leaking subfoveal choroidal neovascular lesion, or CNV currently under active management with anti-VEGF therapy;~* Must be a candidate for anti-VEGF intravitreal injections;~* No previous retinal treatment of photodynamic therapy or laser;~* Able to provide informed consent;~* Able to comply with protocol requirements, including follow-up visits.~Exclusion Criteria:~* Liver enzymes \> 2 X upper limit of normal;~* Any prior treatment for AMD in the study / control eye, excluding anti-VEGF injections;~* Extensive sub-foveal scarring, extensive geographic atrophy, or thick subretinal blood in the study eye as determined by the investigator;~* Significant retinal disease other than sub-foveal CNV AMD;

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose rAAV.sFlt-1 (Type: EXPERIMENTAL): None
- High Dose rAAV.sFlt-1 (Type: EXPERIMENTAL): None
- Control - ranibizumab only (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).